A major contributor to cancer mortality is recurrence and subsequent metastatic transformation following therapeutic intervention. Therefore, in order to develop new treatment modalities and improve the efficacy of current ones, it is important to understand the molecular mechanisms that promote resistance to therapy in cancer cells. One pathway contributing to therapy resistance is autophagy, a self-digestive process that can eliminate unnecessary or damaged organelles to protect cancer cells from death. We have found that the VEGF-C/NRP-2 axis is involved in the activation of autophagy, which helps cancer cell survival following treatment. Inhibition of mTOR complex 1 activity by this axis is the underlying mechanism for the activation of autophagy. Furthermore, we identified two VEGF-C/NRP-2-regulated genes, LAMP-2 and WDFY-1 that have previously been suggested to participate in autophagy and vesicular trafficking.
Introduction
A delicate balance between cell survival and cell death is crucial for maintaining normal physiological homeostasis. This balance is dysregulated in cancer cells via alterations in pathways regulating apoptosis, necrosis, and autophagy, which constitutes an important mechanism of therapeutic resistance.
The recurrence of cancer after therapy arises from a subset of cells that acquire the ability to survive during therapeutic stress. These cells also show enhanced metastatic properties and lead to cancer mortality (1). A key mechanism that confers stress tolerance and enables cancer cells to survive under stress is macroautophagy, most commonly known as autophagy (2, 3) .
Autophagy is a regulated catabolic pathway that promotes lysosomal degradation of damaged proteins, cellular organelles, and other macromolecules (4) (5) (6) (7) (8) (9) . This self-digestion process, which facilitates the recycling of bioenergetic components, is activated by a number of stimuli, including the presence of reactive oxygen species, deprivation of growth factors, DNA damage, and cytotoxic drugs (10) (11) (12) . Autophagy dysregulation is associated with a number of disease states, including cancer (6, 12, 13) . Autophagy plays different roles during the initiation and progression of cancer (2, 14, 15) . While autophagy acts as a tumor suppressor during the initiation phase of cancer, it promotes tumor progression and metastasis in established cancers (2, 16) . Metastatic cancer cells that usually grow in a nutrient-poor microenvironment utilize autophagy to fulfill their high metabolic demand. Autophagy can facilitate survival during anchorage-independent growth or anoikis, and promotes therapeutic resistance (17, 18) . Furthermore, a recent study indicated that genetic or pharmacologic inhibition of autophagy sensitized tumor cells to anti-cancer treatment (19) .
During therapy resistance, autophagy protects cancer cells from necrotic death by removing organelles damaged by treatment with chemotherapeutic drugs (2) .
Autophagy has been demonstrated to be a survival mechanism in castrationresistant prostate cancer cells (20) , (21, 22) . Additionally, pancreatic ductal adenocarcinoma cells display high basal levels of autophagy, which contributes to their intrinsic treatment resistance (23) .
Vascular endothelial growth factor-C (VEGF-C), a member of the VEGF family of proteins, induces the formation of new lymphatic vessels, a process known as lymphangiogenesis (24) . VEGF-C binds to a heterodimer, consisting of one of two tyrosine kinase receptors (VEGFR3 or VEGFR2) and a non-tyrosine kinase receptor, neuropilin-2 (NRP-2), on lymphatic endothelial cells (25) (26) (27) .
Notably, VEGF-C has lymphangiogenesis-independent functions. For example, VEGF-C is often overexpressed in glioblastoma patients, even though brain tissue is void of lymphatics. VEGF-C is also a trophic factor for neural progenitors in vertebrate embryonic brain (28) ; and can stimulate the proliferation and survival of leukemic cells (29, 30) , proliferation and migration of Kaposi's sarcoma cells (31) , and the invasion and metastasis of gastric, breast and lung cancer cells (31) (32) (33) . Detail description of the microarray analysis has been provided in the supplement document.
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Western blot and ELISA: Western blots were conducted using antibodies against LAMP-2 (The Developmental Hybridoma Bank at the University of Iowa), LC3, , pS6K, S6K (Cell Signaling, Billerica, MA), (Ser308), NRP-2 and rho-GDI (Santa Cruz Biotechnology, Santa Cruz, California), ATG13, WDFY-1 (GeneTex, Irvine, CA) and beta-Actin (Sigma, St. Louis, MO). pATG13 (Ser138) (Rockland Immunochemicals, Gibertsville, Pennsylavnia).
Secreted VEGF-C in conditioned media was analyzed using an ELISA kit (R&D Systems, Inc., Minneapolis, MN) according to manufacturer protocol.
Apoptosis assay and confocal microscopy: Vybrant Apoptosis Assay Kit #7, was performed with the data sets obtained to determine whether the differences between experimental groups were significant (p0.05).
To determine the autophagic activity, stably-transfected PC3 cells were grown on poly-L-lysine coated coverslips (BD Biosciences, Sparks, MD). VEGF-C and NRP-2 were depleted 72 hr prior to cell fixation. BAFM and docetaxel at the concentrations listed above were added. At the end of the experiment, the cells were fixed with 4% paraformaldehyde and counter stained with DAPI.
Respective filters were used to image red and green LC-3II puncta. All confocal images were captured in Zeiss 710 Confocal Laser Scanning
Microscope equipped with 4 lasers and images were captured and analyzed using Zeiss Zen 2010 software. For quantification the arithmetic mean intensities of red and green fluorescence images in each field were measured. The ratio of intensities of red fluorescence over green were then calculated and represented
graphically. An increased ratio of red to green corresponds to increased autolysosome formation.
Results:
Disruption of the VEGF-C/NRP-2 axis alters the expression of autophagyrelated genes in prostate cancer cells:
We previously observed that the expression of VEGF-C and NRP-2 promoted the survival of prostate cancer cells following treatment with H 2 O 2 (34).
To identify potential pathways involved in this VEGF-C-mediated cell survival, we performed a microarray study of PC3 prostate cancer cells depleted of either VEGF-C or NRP-2 using SmartPool siRNAs and with scrambled siRNA as a control [Please find the detail microarray data at GEOarchive, Geo accession number GSE36085; NCBI tracking system number 16273855 (36)]. We found 34 gene-tags that were commonly up-or down-regulated in both NRP-2-and VEGF-C-depleted cells. A subset of 10 genes was validated via qPCR ( Figure 1A ). Two genes, LAMP-2 and WDFY-1, were studied in-depth, based upon previous reports of function and cellular localization of the proteins. LAMP-2 plays an important role in autophagy by facilitating the fusion of autophagosomes to lysosomes (37) . WDFY-1 participates in vesicular trafficking (38) and shares homology with WDFY-3, which participates in aggrephagy, a selective process that degrades protein aggregates utilizing the autophagy machinery (39) . We found that both the LAMP-2 and WDFY-1 proteins were up-regulated in PC3 cells following VEGF-C/NRP-2 depletion (Figure 1 , B and C). Since both these proteins are involved in autophagy, we hypothesized that VEGF-C/NRP-2 axis regulates autophagy. Depletion of VEGF-C was confirmed by both ELISA and qPCR (Supplemental Figures 1A and B) , while NRP-2 depletion was confirmed by both qPCR and western blot analysis (Supplemental Figures 1C and D) . suggest the VEGF-C/NRP-2 axis is involved in autophagy maintenance in cancer cells during therapeutic stress.
To confirm that the depletion of VEGF-C or NRP-2 prevents autophagic trafficking, PC3 cells stably expressing a mCherry-GFP-LC3 construct were transfected with VEGF-C or NRP-2 siRNAs, incubated with docetaxel for 48 hrs, and imaged via confocal microscopy. Following autophagic initiation red, yellow or green LC3 punctae are visible (13) . While yellow or green puncta corresponding to autophagosomes, as the autophagosomes mature and fuse with the lysosomes (autolysosome), only red puncta should be visible as GFP is acid-labile, and the lysosomal lumen is highly acidified. As shown in Figure 3F , we saw both small green/yellow puncta as well as large, red, perinuclear structures indicative of autophagic activity in control cells. In VEGF-C-and NRP-2-depleted cells, however, we observed only diffuse green staining or green puncta, indicating a decrease in autolysosomal turn-over and therefore an inhibition of autophagy. When we calculated the ratio between the red and green fluorescence intensities (a measure of autophagy activity) in twenty randomly selected fields for control and VEGF-C-/NRP-2 -depleted cells ( Figure 3G ), we found a decrease in the ratio of red to green which validated our previous results.
Representative images for Figure 3G cancer cells from therapy-induced stress. To determine whether autophagy is involved in the response of cancer cells to docetaxel treatment, PC3 cells were incubated with docetaxel, BAFM, or both agents. Autophagic inhibition by BAFM was confirmed by analyzing mCherry-GFP-LC3-expressing cells using confocal microscopy (Supplemental Figure 8A) . We observed a significant (p=0.0345) increase in cell death following treatment with both docetaxel and BAFM ( Figure   4F and Supplemental Figure 8B ), whereas, we did not observe a significant increase in cell death following docetaxel treatment alone. Overall, the extent of cell death was similar to that observed in VEGF-C-or NRP-2-depleted cells. In order to further show that VEGF-C axis regulated autophagy is important for docetaxel resistance, we performed the following experiments. We CAN-11-3635 inhibitor, Bafilomycin. These results therefore suggest that VEGF-C/NRP-2 axisdependent autophagy is required for its survival promoting function during chemotherapeutic stress. This conclusion was once again validated in PC3 cells (Supplemental Figure 11) . Figure 15 A and B) . These data indicate that the VEGF-C axis promotes autophagy, which contributes to survival in cancer cells exposed to cytotoxic stress. 
Up-regulation of WDFY-1 following VEGF-C and NRP-2 depletion contributes to decreased cell viability in chemotherapy-treated cells
We previously demonstrated that LAMP-2 and WDFY-1 levels increase following VEGF-C and NRP-2 depletion (Figure 1) . We observed a similar increase in LAMP-2 and WDFY-1 following inhibition of autophagy by BAFM treatment in all cell lines ( Figure 6A ). We therefore concluded that the upregulation of WDFY-1 and LAMP-2 occur when autophagy is inhibited through any inhibitory mechanism. Next, we tested whether increases in the levels of WDFY-1 and LAMP-2 influence the survival of cancer cells following therapeutic intervention. We found that VEGF-C depletion led to a significant (p = 0.015) increase in cell death following docetaxel treatment. Intriguingly, the co-depletion of VEGF-C and WDFY-1, which we verified by western blot (Figure 6B Similarly, the depletion of both LAMP-2 and VEGF-C also led to a decrease in cell death compared to the depletion of VEGF-C alone (data not shown), although we did not find that this difference was statistically significant. Together, these results suggest that increased levels of WDFY-1 and LAMP-2 (to a lesser extent) promote cell death following the inhibition of autophagy. unexpected result remained unanswered in our previous publication (34) . As active mTORC1 blocks the induction of autophagy (9), we hypothesized that the VEGF-C/NRP-2 axis actually inhibits mTORC1 activity to promote autophagy during stress (44) . Indeed we observed a significant increase in phospho-S6K following the depletion of either VEGF-C or NRP-2 in PC-3 ( Figure 7A ) or a decrease in phospho-S6K level in docetaxel-treated LNCaP C4-2 cells (34) following VEGF-C addition (Supplemental Figure 17A and B) , suggesting an inhibitory role of VEGF-C axis on mTORC1 activity. This increase in S6K phosphorylation upon VEGF-C depletion seemed to be independent of AKT as knocking down AKT level did not significantly influence phospho S6K level (Supplemental Figure 17C We therefore conclude that the VEGF-C/NRP-2 axis promotes autophagy via downregulation of mTORC1 function especially during therapeutic stress.
Discussion
The ability of tumor cells to survive under stress is a major obstacle to effective cancer therapy (1, 19) . Autophagy has been shown to promote cancer cell survival in the presence of metabolic, hypoxic, or cytotoxic stress (6, 12) (Figure 2 ) and observed an autophagy-inducing function by both VEGF-C and NRP-2. To our knowledge, this is a novel observation and underscores the importance of this axis in cancer stress-resistance. It has been postulated by researchers in this field that autophagy and apoptosis are mutually exclusive (10) . Since autophagy is viewed as primarily cytoprotective, it has been hypothesized that its induction should be coupled with the activation of antiapoptotic pathways (10) . Our previous study on the function of the VEGF-C axis in cancer validates this hypothesis (34) . We previously demonstrated that the VEGF-C axis activates mTORC2 and promotes cancer cell survival during stress through the activation of anti-apoptotic pathways. Our current study suggests that this axis also controls autophagy. We therefore propose that due to its ability to couple autophagy and anti-apoptotic pathways, the VEGF-C/NRP-2 axis is a significant pathway in promoting cancer cell survival during stress.
We then examined the interaction between the VEGF-C axis and autophagy in the presence of docetaxel-induced cytotoxic stress. Docetaxel has been used to treat patients with metastatic, castration-resistant prostate cancer (45) and independent clinical trials have shown that docetaxel-based treatment can increase median overall survival compared to mitoxantrone and prednisone (46, 47) . Docetaxel functions by stabilizing microtubules, thereby inhibiting mitotic spindle depolymerization and cell proliferation. Docetaxel also induces cell death by inhibiting various cell-survival mechanisms. The cell death-inducing function of docetaxel may be therapeutically more significant in prostate cancer as this cancer usually proliferates at a slower rate, and lethality of metastatic castration- 
resistant prostate cancer is due to its ability to resist death (45) . Resistance to docetaxel in men with metastatic castration-resistant disease has been observed in almost 50% of patients. Accordingly, we determined whether the autophagyinducing activity of the VEGF-C axis in prostate cancer cells is responsible for its ability to resist docetaxel-induced cell death. In VEGF-C-and NRP-2-depleted cells treated with docetaxel, we observed decrease in autophagic flux compared to control cells ( Figure 3A-E) . We have confirmed this observation morphologically using mCherry-GFP-LC3-expressing cells ( Figure 3F CAN-11-3635 expression of both VEGF-C and NRP-2 (data not shown). We treated CaPan-1 cells with gemcitabine as it is the standard chemotherapeutic agent used to treat metastatic pancreatic cancer (50) . Like docetaxel, resistance to gemcitabine is the major reason for its limited therapeutic efficacy (50) . We observed a similar decrease in autophagic flux and increase in cell death in both Du145 treated with docetaxel as well as CaPan1 cells treated with gemcitabine ( Figure 5 and Supplemental Figures 4, 9-12 ), which suggests that up-regulation of the VEGF-C axis is a general adaptation that promotes tumor cell survival under adverse conditions. Overall, these data strongly suggest the importance of this axis in autophagic activation.
Although the increased levels of WDFY-1 and LAMP-2 (to a lesser extent)
following VEGF-C and NRP-2 depletion can function in the induction of cell death ( Figure 6 and Supplemental Figure 13 ), they are not likely to be involved in regulating autophagy. In future studies we will unravel their roles in promoting cell death following autophagy inhibition. Our finding that the VEGF-C axis inhibits mTORC1 to activate autophagy (Figure 7) is novel and provides a mechanism through which this axis promotes resistance against treatment.
In conclusion, we have established that the VEGF-C/NRP-2 axis is important in the activation of autophagy following treatment with chemotherapy.
Our data suggest that VEGF-C-induced autophagy protects cancer cells from the cytotoxic stress-induced death as well as the potential of the VEGF-C axis as a therapeutic target. Our future studies will focus on determining the mechanism(s) through which WDFY-1 activates cell death downstream of autophagy inhibition. Author Manuscript Published OnlineFirst on November 13, 2012; DOI: 10.1158/0008-5472. Unraveling these signaling pathways may assist in the development of novel treatments to overcome chemotherapy resistance. 
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